BridgeBio Pharma, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company generated total revenues of $110.6 million for the quarter, a substantial increase from $2.2 million in the same period last year. This growth was primarily driven by net product revenue of $71.5 million from its commercial product, Attruby, which received FDA approval in November 2024. Additionally, license and services revenue rose to $37.4 million, largely due to a regulatory milestone payment of $30 million recognized under the Eidos-Alexion License Agreement. For the six months ended June 30, 2025, total revenues reached $227.2 million, compared to $213.3 million in the prior year.
Despite the increase in revenue, BridgeBio reported a net loss of $183.8 million for the quarter, compared to a loss of $75.5 million in the same quarter of 2024. The loss for the first half of 2025 was $353.4 million, significantly higher than the $111.7 million loss reported for the same period in 2024. The increase in losses was attributed to higher operating costs, particularly in research and development, which totaled $111.2 million for the quarter, and selling, general, and administrative expenses, which surged to $129.2 million, reflecting investments in the commercialization of Attruby.
Operationally, BridgeBio has made strategic moves to enhance its market position. The company completed a $575 million offering of 2031 convertible notes in February 2025, which provided significant liquidity. Additionally, it entered into a Royalty Interest Purchase and Sale Agreement, generating $300 million in cash. The company also reported a cash balance of $749 million as of June 30, 2025, up from $681 million at the end of 2024, indicating a strong liquidity position to support ongoing operations and development efforts.
BridgeBio's workforce has also seen changes, with a focus on restructuring to streamline operations and reduce costs. The company has been actively managing its research and development pipeline, which includes several late-stage product candidates. The company anticipates continued investment in its product candidates, which may lead to further operating losses in the near term. Looking ahead, BridgeBio expects to continue incurring losses as it focuses on the commercialization of Attruby and the development of its other product candidates, while also navigating the complexities of the biopharmaceutical market.
About BridgeBio Pharma, Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.